SKU: R041  / 
    CAS Number: 13292-46-1

    Rifampicin Solution (10mg/mL in water), sterile filtered

    $0.00 - $121.91
    Rifampicin Solution (10mg/mL in water), sterile filtered
    Rifampicin Solution is fully soluble in water, our pre-made stock solutions are easier to handle and safer then the methanol or DMSO solution alternatives. This aqueous formulation is easy to use simply add 1ml to 3ml per liter of desired media.

    Rifampicin is a broad-spectrum antibiotic, it is not soluble in water and is mostly sold in powder forms. Weighting small amounts of Rifampicin is a tedious job and it can be difficult to avoid human inhalation. Normally, a stock solution of Rifampicin is prepared by dissolving it in methanol which is toxic to many plant cells as well as other cells. Our aqueous solution of Rifampicin is much more user-friendly and non-toxic to these cells.


    For Rifampicin powder CLICK HERE

    For Rifampicin Sodium CLICK HERE
    Mechanism of ActionRifampicin targets prokaryotic DNA dependent RNA polymerases which prevent subsequent RNA transcription and protein translation.
    Spectrum

    Rifampicin is a broad-spectrum antibiotic with a wide range of activity including: 

    • Gram-positive aerobic bacteria, particularly Staphylococcus spp and Rhodococcus equi
    • Brucella and some other fastidious organisms are susceptible but Gram-negative bacteria more generally are resistant
    • Gram-positive and Gram-negative anaerobic bacteria are inhibited at low concentrations, including Bacteroides fragilis
    • Chlamydophila and Rickettsia are susceptible
    • Mycobacterium tuberculosis: activity is high against this organism but most other mycobacteria are resistant
    • Some protozoa
    • Some fungi and poxviruses
    Microbiology ApplicationsRifampicin is commonly used in bacterial recombinant protein expression to inhibit bacterial RNA polymerase activity and synthesis of host bacterial proteins. Rifampicin can also be used as a selective agent to isolate Campylobacter jejuni.

    Rose et al. used rifampicin from TOKU-E in methacrylate-based copolymer films and studied its effects on biofilm formation: "Prevention of Biofilm Formation by Methacrylate-Based Copolymer Films Loaded With Rifampin, Clarithromycin, Doxycycline Alone or in Combination."



    Plant Biology ApplicationsRifampicin has been tested in Jerusalem artichoke tuber explants by adding 10 to 50 µg/ml to the tissue culture medium. At 50 µg/ml no bacterial infection was detectable, without affecting cell division rates, cytodifferentiation and DNA synthesis. As a result, Rifampicin was used as antibacterial in the following experiments of this university department (Philips, 1981).
    Eukaryotic Cell Culture Applications

    Rifampicin has been shown to have immunosuppressive effects in mice.  There are no immunosuppressive effects in humans when rifampicin is given in doses at or below clinically recommended levels.

    Rifampicin has been shown to inhibit α-synuclein fibrillation and disaggregate fibrils in a concentration-dependent manner. Rifampicin can activate pregnane X receptor (PXR), which affects cytochrome P450, and the activity of glucuronosyltransferases and P-glycoprotein. Rifampicin has been shown to enhance CYP2C-mediated metabolism, affect compounds that are transported by P-glycoprotein and metabolized by CYP3A4.

    Molecular FormulaC43H58N4O12
    References

    "Rifampin: Mechanisms of Action and Resistance." Oxford Journals (1983): n. pag. Clinical Infectious Diseases. Web. 21 Aug. 2012.

    "Philips R., Arnott S.M. and K aplan S.E., 1981, Antibiotics in plant tissue culture: rifampicin effectively controls bacterial contaminants without affecting the growth of short-term explant cultures of Helianthus tuberosus. Plant Science Letters, 21 (1981) 235-240.

    Li, T., & Chiang, J. Y. (2006). Rifampicin induction of CYP3A4 requires pregnane X receptor cross talk with hepatocyte nuclear factor 4alpha and coactivators, and suppression of small heterodimer partner gene expression. Drug metabolism and disposition: the biological fate of chemicals, 34(5), 756-64.

    Jill E Maddison, A David J Watson, Jonathan Elliott (2008) Chapter 8 - Antibacterial drugs, Small Animal Clinical Pharmacology (Second Edition), 148-185.

    Bassi, L., Berardino, L., Arioli, V., Silvestri, L., & Lignière, E. (1973). Conditions for Immunosuppression by Rifampicin. The Journal of Infectious Diseases, 128(6), 736-744.